For adults with mild-to-moderate COVID-19, early administration of simnotrelvir plus ritonavir shortens the time to sustained resolution of symptoms, according to a study published in the Jan. 18 issue of the New England ...
Jan 18, 2024
0
0
For children with achondroplasia, vosoritide is associated with a gain in the change in height Z score from baseline and a mild adverse event profile, according to a study published in the January issue of The Lancet Child ...
Dec 30, 2023
0
0
A new treatment appears to reduce food allergies in children and teens, according to interim clinical trial results.
Dec 21, 2023
0
2
Prof. Mark Coburn and PD Dr. Ana Kowark from the Department of Anesthesiology and Operative Intensive Care Medicine at the University Hospital Bonn (UKB) have conducted the largest randomized study to date on the effect of ...
Dec 20, 2023
0
0
A single dose of mRNA-1345 vaccine is safe and results in lower incidence of respiratory syncytial virus (RSV)-associated disease in older patients, according to a study published in the Dec. 14 issue of the New England Journal ...
Dec 14, 2023
0
2
For pregnant women with type 2 diabetes, the addition of metformin to insulin does not affect composite adverse neonatal outcomes, according to a study published in the Dec. 12 issue of the Journal of the American Medical ...
Dec 12, 2023
0
0
A new research article from Thomas Stewart, an associate professor of data science at the University of Virginia, examining the COVID-19 treatment fluvoxamine has been published in JAMA.
Nov 20, 2023
0
0
The use of gantenerumab leads to lower amyloid plaque burden at 116 weeks, but is not associated with slower clinical decline among patients with early Alzheimer disease, according to a study published in the Nov. 16 issue ...
Nov 16, 2023
0
0
In a finding that could change the landscape of heart disease care, the wildly popular weight-loss drug Wegovy has proved its mettle in protecting the heart after lowering the risk of cardiac problems in patients by 20%.
Nov 13, 2023
0
0
A new PCSK9 inhibitor (recaticimab) injected every one to three months may work safely and provide more flexible dosing to lower cholesterol, according to late-breaking science presented today at the American Heart Association's ...
Nov 13, 2023
0
0
